EPIX Form 25 Filed by Nasdaq to Remove Listing

Rhea-AI Filing Summary

Nasdaq has submitted a Form 25 to remove the listing of ESSA Pharma Inc. The filing names the issuer as ESSA Pharma Inc. (symbol EPIX) with principal offices in Vancouver, British Columbia. The form cites compliance with the Exchange's procedures under the federal rules that govern delisting and voluntary withdrawal but does not state the reason, effective date, or indicate which specific rule provision was checked. No financial results, transactions, or timelines are included.

Positive

• None.

Negative

• Listing removal notice filed without an effective date or reason disclosed

Insights

Exchange Compliance Specialist

Form 25 notifies investors that the company's Nasdaq listing will be removed, without stating a date or reason.

The filing confirms that Nasdaq submitted a Form 25 for ESSA Pharma Inc. (EPIX) and asserts compliance with the Exchange's internal rules and applicable federal regulations for delisting or voluntary withdrawal. The document lists the issuer's principal address and contact number but includes no operational or financial details explaining the action.

The main dependencies are procedural: whether the removal is voluntary or initiated by Nasdaq and the timing of the removal. Absent a stated effective date or cause, the near-term item to watch is any follow-up filing (an attached Notice or a company statement) that discloses the effective date or reason within typical regulatory timelines.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37410

Issuer:	ESSA Pharma Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	999 West Broadway, Suite 720
	Vancouver	BRITISH COLUMBIA, CANADA	V5Z 1K5
Telephone number:					(778)-331-0962

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-10-09	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filed for ESSA Pharma (EPIX) mean?

The Form 25 indicates Nasdaq has submitted a notification to remove or withdraw the company's class of securities from Nasdaq listing; the filing does not state an effective date or the reason.

Does the filing say whether the delisting was voluntary or involuntary for EPIX?

No. The filing states compliance with Exchange rules for delisting and withdrawal but does not specify whether the action is voluntary or initiated by Nasdaq.

What company contact information is included in the Form 25 for ESSA Pharma?

The filing lists the issuer's address as 999 West Broadway, Suite 720, Vancouver, British Columbia and telephone number (778)-331-0962.

Are there any financial results or transactions disclosed in this Form 25?

No. The filing contains no earnings data, financial tables explaining the action, or transaction details.

What should investors watch for after this Form 25 filing for EPIX?

Investors should look for follow-up disclosures that provide an effective date, the specific rule provision applied, or a company statement explaining the reason for removal.